Copyright © 2026 Authors retain the copyright of this article. This article is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

@article{191309,
        author = {Tanaya rajesh khirapate and Reema Rani and Dr. Rupali Tasgaonkar},
        title = {PEGylation in biophrmaceutics: An evolving strategy for enhanced therapeutic efficacy},
        journal = {International Journal of Innovative Research in Technology},
        year = {2026},
        volume = {12},
        number = {8},
        pages = {6494-6497},
        issn = {2349-6002},
        url = {https://ijirt.org/article?manuscript=191309},
        abstract = {PEGylation is the process of attaching polyethylene glycol (PEG) chains to therapeutic molecules, it has played a transformative role in the development of biopharmaceuticals (1,9).
This strategy helps improve drug solubility, stability, and half-life, and has been especially valuable in protein- and peptide-based therapeutics (1,4).
Over the years, PEGylation has contributed to the success of multiple FDA-approved drugs, enhancing their performance and patient tolerability (1,10).
However, it is not without challenges (5,10).
The emergence of anti-PEG antibodies, potential loss of biological activity, and concerns about long-term PEG accumulation have highlighted the need for more refined approaches (3,5,13).
This review explores the basic science of PEGylation, examines its clinical applications, addresses current limitations, and looks ahead at innovative solutions shaping its future (4,9,10).},
        keywords = {PEGylation, Biopharmaceutical, Immunogenicity, Drug delivery systems, Controlled release, Anti-PEG antibodies},
        month = {January},
        }